कृपया अन्य खोज का प्रयास करें
| चिन्ह | एक्सचेंज | करेंसी | ||
|---|---|---|---|---|
| SYNN | NSE | INR | रियल टाइम | |
| SYNNc1:NS | NSE | INR | देरी | |
| SYNNc2:NS | NSE | INR | देरी | |
| SYNN | BSE | INR | देरी |
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
| नाम | आयु | पहले | शीर्षक |
|---|---|---|---|
| Sharmila Abhay Karve | 57 | 2019 | Additional Independent Director |
| Kiran Mazumdar-Shaw | 70 | 2011 | Non-Executive Chairperson |
| Jonathan Brittan Hunt | 54 | 2016 | MD, CEO & Executive Director |
| Nilanjan Roy | 58 | 2024 | Additional Independent Director |
| Catherine Patricia Rosenberg | 63 | 2000 | Non-Executive Director |
| Vijay Kumar Kuchroo | 69 | 2017 | Independent Director |
| Vinita Bali | 69 | 2017 | Lead Independent Director |
| Sharmila Abhay Karve | 59 | 2019 | Additional Independent Director |
| Kush M. Parmar | 44 | 2021 | Independent Non Executive Director |
| Manja Boerman | - | 2024 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है
